Johnson & Johnson: 3 Key Takeaways for Long-Term Investors

Johnson & Johnson raised its full-year sales outlook after Q3 2026 operational revenue grew 6%, putting the company on track to exceed $100 billion in annual revenue for the first time. Strong pharmaceutical demand, particularly in cancer treatments, drove performance. However, the medical device segment faced headwinds with only 2.5% growth due to Middle East disruptions and China's bulk-buying program. Management plans to restore momentum through new product launches and is leaning toward spinning off its DePuy Synthes orthopedics subsidiary by mid-2027.

10/16/2026, 1:54 PM • The Motley Fool

6 Blue Chip Stocks Trading Well Below Their Highs

Six major blue-chip stocks—Nike, Goldman Sachs, Intel, Disney, Pfizer, and Home Depot—are trading at least 20% below their all-time highs despite a strong bull market. The article analyzes each stock to determine whether they represent bargains or value traps, considering factors like valuation metrics, competitive pressures, and market sentiment.

10/16/2026, 5:30 AM • The Motley Fool

2 High-Yield Dividend Stocks Worth Buying Before 2026 Ends

Verizon Communications and Pfizer are highlighted as attractive high-yield dividend stocks for income investors. Verizon offers a 6.5% forward dividend yield backed by strong subscriber growth and improved customer retention, while Pfizer provides a 6.1% yield with a 352-consecutive-quarter dividend history and growth potential from its oncology pipeline and 96 research programs.

10/15/2026, 4:23 PM • The Motley Fool

Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight

Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results.

10/15/2026, 1:00 PM • GlobeNewswire

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures.

10/15/2026, 10:16 AM • The Motley Fool

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential.

10/13/2026, 8:17 AM • The Motley Fool

How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?

To generate $1,000 monthly in dividend income ($12,000 annually), investors should diversify across five pharmaceutical stocks rather than concentrating in high-yield Pfizer alone. Investing $70,000 each in Pfizer, Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Amgen creates a balanced portfolio that reduces risk from patent expirations and potential dividend cuts while maintaining steady income.

10/10/2026, 10:15 PM • The Motley Fool

Next Generation Antibody Therapeutics Market, 2nd Edition: Global Industry Trends and Forecast to 2035 | Immunocytokines and Combination Therapies Drive Growth

The global next generation antibody therapeutics market is projected to grow from USD 5.45 billion to USD 5.76 billion by 2035, with a modest 1% CAGR. Growth is driven by advances in biotechnology, targeted treatments, and expanding clinical pipelines for cancer, rare diseases, and cardiovascular conditions. Immunocytokines and combination therapies are expected to demonstrate the strongest growth potential, while North America is projected to maintain approximately 64% market share.

10/09/2026, 5:36 AM • GlobeNewswire

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

The article compares Bristol Myers Squibb and Pfizer as healthcare investment options for 2026. Both face patent cliffs and regulatory pressures, but Pfizer is recommended as the better choice due to its clearer post-patent roadmap, growing non-COVID products, obesity drug positioning, and committed dividend protection. Bristol Myers Squibb shows near-term momentum improvements but faces longer-term revenue uncertainty from patent losses and drug pricing reforms.

10/08/2026, 8:43 PM • The Motley Fool

3 of the Best Dividend Stocks to Buy in October 2026

As valuations remain high in 2026, the article recommends three dividend stocks as safer investment options: Pfizer (6.3% yield, trading at 10x earnings despite 35% decline), ExxonMobil (2.5% yield, up 37% this year with decades of dividend growth), and Realty Income (6.1% yield with monthly payouts and strong stability).

10/06/2026, 12:30 PM • The Motley Fool

Freehand CEO Nitin Jayakrishnan Addresses Supply Chain Disruption and Resilience at LogiPharma USA 2026

Freehand, an AI workforce platform for procurement and accounts payable operations, showcased its solutions at LogiPharma USA 2026. CEO Nitin Jayakrishnan participated in a keynote panel discussing supply chain resilience in the pharmaceutical industry. The company, which serves major healthcare enterprises including Johnson & Johnson and Pfizer, recently raised $75 million in funding to scale its AI Teams that automate complex procurement and spend management processes.

10/06/2026, 7:00 AM • GlobeNewswire

Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock

Eli Lilly, the only healthcare stock in the trillion-dollar club, has rallied 400% over five years driven by its successful GLP-1 drugs Mounjaro and Zepbound. However, with a valuation of 40x trailing earnings and slowing growth prospects, the stock faces significant headwinds from intensifying competition in the GLP-1 market from companies like Pfizer and Viking Therapeutics. The author suggests the stock may have more downside risk than upside potential at current valuations.

10/05/2026, 4:20 PM • The Motley Fool

Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?

Both Pfizer and Novo Nordisk face significant dividend safety concerns despite high yields. Novo Nordisk (4.7% yield) leads in GLP-1 drugs but has lost market share to Eli Lilly and lacks portfolio diversity, while Pfizer (6% yield) faces patent expirations and R&D challenges. However, Pfizer's broader product portfolio and acquisition strategy make it the relatively safer choice for dividend investors, despite both stocks carrying material risk.

10/04/2026, 5:15 PM • The Motley Fool

Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP

VanEck Pharmaceutical ETF (PPH) offers lower costs (0.36% expense ratio) and higher dividend yield (2%), making it better for long-term buy-and-hold investors. Invesco Pharmaceuticals ETF (PJP) delivered stronger 1-year returns (41% vs 31%) with more balanced U.S.-focused holdings, but charges higher fees (0.58%) and offers lower yield (0.9%).

10/02/2026, 8:13 PM • The Motley Fool

Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Novo Nordisk and Pfizer are compared as pharmaceutical giants navigating different challenges. Novo Nordisk boasts superior profitability with a 33% net margin and strong cash flow, but faces pricing pressures and competition in the GLP-1 weight-loss drug market. Pfizer trades at lower valuations and is improving net income through strategic acquisitions in oncology and obesity, though it faces significant patent cliffs through 2030. The article recommends Pfizer as the better buy in 2026 based on its value metrics and improving earnings trajectory.

10/02/2026, 12:15 PM • The Motley Fool